American Association for Cancer Research

Table 1.

Patient characteristics at the time of bone marrow sampling

Patient no.	Stage (AJCC)	Age (y)	Disease duration (mo)*	LDH (units/L)	Location of metastases	Tumor load	Previous therapy	Current therapy	Bone marrow response (frequency)^†	Peripheral blood response (frequency)
1	I	33	1	134	NED	No	None	None	Negative	POS (8/10⁵)
2	I	50	0	173	NED	No	None	None	Negative	Negative
3	I	72	1	168	NED	No	None	None	Negative	Negative
4	I	65	61	188	NED	No	None	None	Negative	Negative
5	I	64	7	160	NED	No	Ifn-a	None	Negative	Negative
6	II	52	1	NA	NED	No	None	None	Negative	Negative
7	II	52	31	201	NED	No	Ifn-a	None	Negative	Negative
8	II	42	1	NA	NED	No	None	None	Negative	Negative
9	II	55	1	NA	NED	No	None	None	Negative	POS (88/10⁵)
10	III	78	9	143	Lymph node	Yes	None	None	Negative	Negative
11	III	53	2	187	NED	No	None	None	Negative	Negative
12	III	38	1	196	NED	No	None	None	Negative	Negative
13	III	44	7	158	NED	No	None	IFN-α	Negative	Negative
14	III	54	1	201	NED	No	None	None	Negative	POS (13/10⁵)
15	III	54	0	206	NED	No	None	None	Negative	Negative
16	III	58	6	161	NED	No	None	Peptide-pulsed dendritic cell	Negative	Negative
17	III	63	1	162	NED	No	None	None	Negative	Negative
18	III	71	3	199	NED	No	None	None	Negative	Negative
19	III	70	17	NA	NED	No	Ifn-a	Ifn-a	POS (40/10⁵)	Negative
20	IV	34	3	173	NED	No	None	None	Negative	Negative
21	IV	37	13	174	NED	No	Peptide vaccination	None	Negative	Negative
22	IV	39	41	185	Lymph node	Yes	None	Temozolomide + IFN-α	Negative	Negative
23	IV	40	7	293	Lymph node	Yes	None	Peptide-pulsed dendritic cell	Negative	Negative
24	IV	42	83	197	NED	No	IFN-α, peptide vaccination	None	POS (169/10⁵)	Negative
25	IV	42	0	160	NED	No	None	None	Negative	Negative
26	IV	44	60	487	Skin, lymph node, brain, lung, spleen, liver	Yes	Dacarbazine + IFN-α	Temozolomide	POS (4/10⁵)	Negative
27	IV	44	18	419	Skin, lung	Yes	IFN-α	Peptide vaccination	Negative	Negative
28	IV	46	11	173	NED	No	IFN-α	None	Negative	Negative
29	IV	48	1	287	Lymph node, lung, brain	Yes	None	None	POS (251/10⁵)	Negative
30	IV	56	36	197	Lymph node, spleen, bone	Yes	IFN-α, peptide-pulsed dendritic cell	Temozolomide	Negative	Negative
31	IV	58	3	284	Bone	Yes	Radiation	None	Negative	Negative
32	IV	58	6	237	Liver	Yes	IFN-α	None	Negative	Negative
33	IV	58	26	NA	Peritoneum	Yes	IFN-α	Temozolomide + IFN-α	POS (131/10⁵)	POS (222/10⁵)
34	IV	60	92	157	NED	No	Radiation, IFN-α	Peptide vaccination	Negative	Negative
35	IV	65	1	180	Lung, bone	Yes	None	None	Negative	Negative
36	IV	67	137	372	Lymph node, lung, kidney	Yes	Dacarbazine + IFN-α	Imatinib	Negative	Negative
37	IV	68	13	187	Skin	No	IFN-α	Peptide vaccination	POS (30/10⁵)	Negative
38	IV	71	7	111	Lymph node	Yes	None	None	Negative	Negative
39	IV	78	67	NA	Lung	Yes	None	None	Negative	Negative
40	IV	38	62	NA	Lung	Yes	Temozolomide	Temozolomide	POS (68/10⁵)	Negative

Patient no.	Stage (AJCC)	Age (y)	Disease duration (mo)*	LDH (units/L)	Location of metastases	Tumor load	Previous therapy	Current therapy	Bone marrow response (frequency)^†	Peripheral blood response (frequency)
1	I	33	1	134	NED	No	None	None	Negative	POS (8/10⁵)
2	I	50	0	173	NED	No	None	None	Negative	Negative
3	I	72	1	168	NED	No	None	None	Negative	Negative
4	I	65	61	188	NED	No	None	None	Negative	Negative
5	I	64	7	160	NED	No	Ifn-a	None	Negative	Negative
6	II	52	1	NA	NED	No	None	None	Negative	Negative
7	II	52	31	201	NED	No	Ifn-a	None	Negative	Negative
8	II	42	1	NA	NED	No	None	None	Negative	Negative
9	II	55	1	NA	NED	No	None	None	Negative	POS (88/10⁵)
10	III	78	9	143	Lymph node	Yes	None	None	Negative	Negative
11	III	53	2	187	NED	No	None	None	Negative	Negative
12	III	38	1	196	NED	No	None	None	Negative	Negative
13	III	44	7	158	NED	No	None	IFN-α	Negative	Negative
14	III	54	1	201	NED	No	None	None	Negative	POS (13/10⁵)
15	III	54	0	206	NED	No	None	None	Negative	Negative
16	III	58	6	161	NED	No	None	Peptide-pulsed dendritic cell	Negative	Negative
17	III	63	1	162	NED	No	None	None	Negative	Negative
18	III	71	3	199	NED	No	None	None	Negative	Negative
19	III	70	17	NA	NED	No	Ifn-a	Ifn-a	POS (40/10⁵)	Negative
20	IV	34	3	173	NED	No	None	None	Negative	Negative
21	IV	37	13	174	NED	No	Peptide vaccination	None	Negative	Negative
22	IV	39	41	185	Lymph node	Yes	None	Temozolomide + IFN-α	Negative	Negative
23	IV	40	7	293	Lymph node	Yes	None	Peptide-pulsed dendritic cell	Negative	Negative
24	IV	42	83	197	NED	No	IFN-α, peptide vaccination	None	POS (169/10⁵)	Negative
25	IV	42	0	160	NED	No	None	None	Negative	Negative
26	IV	44	60	487	Skin, lymph node, brain, lung, spleen, liver	Yes	Dacarbazine + IFN-α	Temozolomide	POS (4/10⁵)	Negative
27	IV	44	18	419	Skin, lung	Yes	IFN-α	Peptide vaccination	Negative	Negative
28	IV	46	11	173	NED	No	IFN-α	None	Negative	Negative
29	IV	48	1	287	Lymph node, lung, brain	Yes	None	None	POS (251/10⁵)	Negative
30	IV	56	36	197	Lymph node, spleen, bone	Yes	IFN-α, peptide-pulsed dendritic cell	Temozolomide	Negative	Negative
31	IV	58	3	284	Bone	Yes	Radiation	None	Negative	Negative
32	IV	58	6	237	Liver	Yes	IFN-α	None	Negative	Negative
33	IV	58	26	NA	Peritoneum	Yes	IFN-α	Temozolomide + IFN-α	POS (131/10⁵)	POS (222/10⁵)
34	IV	60	92	157	NED	No	Radiation, IFN-α	Peptide vaccination	Negative	Negative
35	IV	65	1	180	Lung, bone	Yes	None	None	Negative	Negative
36	IV	67	137	372	Lymph node, lung, kidney	Yes	Dacarbazine + IFN-α	Imatinib	Negative	Negative
37	IV	68	13	187	Skin	No	IFN-α	Peptide vaccination	POS (30/10⁵)	Negative
38	IV	71	7	111	Lymph node	Yes	None	None	Negative	Negative
39	IV	78	67	NA	Lung	Yes	None	None	Negative	Negative
40	IV	38	62	NA	Lung	Yes	Temozolomide	Temozolomide	POS (68/10⁵)	Negative

NOTE: Staging was done according to AJCC criteria (12).

Abbreviations: NED, no evidence of disease; POS, positive ELISpot result (i.e., melanoma reactivity).

Time period between diagnosis and analysis of tumor-reactive T cells.

†

Frequencies of melanoma-reactive T cells were calculated from samples with positive ELISpot results as the difference between mean spot numbers in test wells and mean spot numbers in control wells per 10⁵ total T cells.

View Large

This Feature Is Available To Subscribers Only